77 results
6-K
EX-1.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
for in a company’s articles of association and in certain circumstances by the Company’s Audit Committee or the Company’s Compensation Committee, by the Board … of Directors itself and by the shareholders. The vote required by the Audit Committee, Compensation Committee and the Board of Directors for approval
6-K
EX-99.1
kboqnl4b8vajm2j0
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.2
vl2e d95m02zxtzfel
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
6-K
EX-99.1
wo5fhqsf8f7
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
6-K
EX-99.1
n1ef5vqqyd8w8lc2
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-10.1
u32k5usshaxj 2v
30 Dec 22
Report of Foreign Private Issuer
4:02pm
424B5
pnvp270h
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
mhixoaf
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
F-3
pnmiq32 flvv61mdb
29 Apr 22
Shelf registration (foreign)
8:14am